Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma
Michael S. Khodadoust, Tatyana Feldman, Dok Hyun Yoon, Costas K. Yannakou, Dejan Radeski, Youn H. Kim, Neha Mehta–Shah, Amit Khot, Ryan A. Wilcox, Won Seog Kim, Steven M. Horwitz, Joseph J. Buggy, Andrew Hotson, Craig Hill, Brian Munneke, Suresh Mahabhashyam, Richard A. Miller, James W. Janc, Mehrdad Mobasher (2020). Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma. , 136(Supplement 1), DOI: https://doi.org/10.1182/blood-2020-137782.
